IL115335A - Naphthyl compounds process for their preparation and pharmaceutical compositions thereof - Google Patents

Naphthyl compounds process for their preparation and pharmaceutical compositions thereof

Info

Publication number
IL115335A
IL115335A IL11533595A IL11533595A IL115335A IL 115335 A IL115335 A IL 115335A IL 11533595 A IL11533595 A IL 11533595A IL 11533595 A IL11533595 A IL 11533595A IL 115335 A IL115335 A IL 115335A
Authority
IL
Israel
Prior art keywords
alkyl
pyrrolidinyl
preparation
pharmaceutical compositions
ococ6h5
Prior art date
Application number
IL11533595A
Other languages
English (en)
Other versions
IL115335A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority to IL12831095A priority Critical patent/IL128310A/en
Publication of IL115335A0 publication Critical patent/IL115335A0/xx
Priority to IL12831099A priority patent/IL128310A0/xx
Publication of IL115335A publication Critical patent/IL115335A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrrole Compounds (AREA)
  • Silicon Polymers (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL11533595A 1994-09-20 1995-09-18 Naphthyl compounds process for their preparation and pharmaceutical compositions thereof IL115335A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL12831095A IL128310A (en) 1994-09-20 1995-09-18 Intermediates for naphthyl compounds and processes for their preparation
IL12831099A IL128310A0 (en) 1994-09-20 1999-02-01 Intermediates for naphthyl compounds processes for their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/309,525 US7501441B1 (en) 1994-09-20 1994-09-20 Naphthyl compounds, intermediates, processes, compositions, and methods

Publications (2)

Publication Number Publication Date
IL115335A0 IL115335A0 (en) 1995-12-31
IL115335A true IL115335A (en) 2000-07-26

Family

ID=23198583

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11533595A IL115335A (en) 1994-09-20 1995-09-18 Naphthyl compounds process for their preparation and pharmaceutical compositions thereof

Country Status (29)

Country Link
US (6) US7501441B1 (xx)
EP (1) EP0703228B1 (xx)
JP (1) JPH10506392A (xx)
KR (1) KR970705983A (xx)
AT (1) ATE214058T1 (xx)
AU (1) AU697114B2 (xx)
BR (1) BR9508967A (xx)
CA (1) CA2200449A1 (xx)
CO (1) CO4410318A1 (xx)
CZ (1) CZ291207B6 (xx)
DE (1) DE69525699T2 (xx)
DK (1) DK0703228T3 (xx)
ES (1) ES2173154T3 (xx)
HU (1) HUT77919A (xx)
IL (1) IL115335A (xx)
MX (1) MX9702154A (xx)
MY (1) MY132075A (xx)
NO (1) NO307929B1 (xx)
NZ (1) NZ294177A (xx)
PE (1) PE47496A1 (xx)
PL (1) PL319454A1 (xx)
PT (1) PT703228E (xx)
RU (1) RU2165924C2 (xx)
SI (1) SI0703228T1 (xx)
TR (1) TR199501135A2 (xx)
TW (1) TW399036B (xx)
WO (1) WO1996009039A1 (xx)
YU (1) YU61595A (xx)
ZA (1) ZA957857B (xx)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2162586C (en) 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5998401A (en) 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US6391892B1 (en) * 1995-03-10 2002-05-21 Eli Lilly And Company Naphthyl pharmaceutical compounds
US6451817B1 (en) * 1995-03-10 2002-09-17 Eli Lilly And Company Alpha-substituted-1-benzyl-napthyls
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
GB2312844A (en) * 1996-05-07 1997-11-12 Lilly Co Eli A naphthyl compound for the treatment of immune-complex diseases
SI0826679T1 (en) * 1996-08-29 2002-04-30 Eli Lilly And Company Naphthyl compounds and compositions
CA2213814A1 (en) * 1996-08-29 1998-02-28 Henry Uhlman Bryant Naphthalene compounds, intermediates, formulations, and methods
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
US6599920B2 (en) * 1996-08-29 2003-07-29 Eli Lilly And Company Naphthalene compounds, intermediates, formulations, and methods
CA2214070C (en) * 1996-08-29 2006-03-14 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
CA2214931A1 (en) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Tetrahydrobenzo-a-fluorene compounds and method of use
CA2214196A1 (en) * 1996-09-26 1998-03-26 Eli Lilly And Company Benzo[b]indeno[2,1-d]thiophene compounds, intermediates, processes, compositions and methods
CA2214929A1 (en) * 1996-09-26 1998-03-26 Charles Willis Lugar, Iii Naphthofluorene compounds, intermediates, compositions and methods
CA2215856A1 (en) * 1996-09-26 1998-03-26 Eli Lilly And Company Dihydrobenzofluorene compounds, intermediates, compositions, and methods
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2215647A1 (en) * 1996-10-24 1998-04-24 Eli Lilly And Company Naphthyl compounds, compositions, and methods
CA2216592C (en) * 1996-10-24 2006-07-18 Brian Stephen Muehl Benzothiophene compounds, intermediates, compositions, and methods
CA2214872C (en) * 1996-10-24 2002-01-22 Eli Lilly And Company Benzothiophene compounds, compositions and methods
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
IT1298159B1 (it) * 1997-01-28 1999-12-20 Hoffmann La Roche Derivati di un 5-aroilnaftalene
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
JP2002510289A (ja) * 1997-04-25 2002-04-02 イーライ・リリー・アンド・カンパニー Ｓｅｒｍとしての活性を持つインデン化合物
CA2298651A1 (en) 1997-08-07 1999-02-18 Jeffrey Alan Dodge 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
US6090843A (en) * 1997-08-11 2000-07-18 Eli Lilly And Company Benzothiophenes compounds which have useful pharmaceutical activity
US5929090A (en) * 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
US5834488A (en) * 1997-09-19 1998-11-10 Eli Lilly And Company Dihydrobenzo B! indeno 2, 1-D! thiophene compounds, intermediates, processes, compositions and methods
CA2306489A1 (en) 1997-10-03 1999-04-15 Mark Gregory Stocksdale Benzothiophenes
US6060488A (en) * 1998-09-22 2000-05-09 Eli Lilly And Company Benzothiophenes for treating estrogen deficiency
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
ES2236536T3 (es) 2001-05-22 2005-07-16 Eli Lilly And Company Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos.
PL374845A1 (en) 2002-07-22 2005-11-14 Eli Lilly And Company Selective estrogen receptor modulators containing a phenylsulfonyl group
US20060167051A1 (en) * 2003-02-25 2006-07-27 Remick David M Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
NZ541126A (en) * 2003-02-25 2008-07-31 Lilly Co Eli Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
MXPA05009098A (es) 2003-02-25 2005-11-17 Lilly Co Eli Clorhidrato de 1- (4-(2 -piperidiniletoxifenoxi) -2-(4-metansulfonilfenil) -6-hidroxinaftaleno cristalino no solvatado.
CN100569747C (zh) * 2003-03-31 2009-12-16 科学与工业研究会 巯基-苯基-萘基-甲烷衍生物及其制备
BRPI0414448A (pt) * 2003-09-19 2006-11-14 Pfizer Prod Inc composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e um agonista/antagonista de estrogênio
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
BRPI0417621A (pt) * 2003-12-17 2007-04-10 Pfizer Prod Inc terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea
EP1709023B1 (en) 2004-01-22 2009-11-11 Eli Lilly And Company Selective estrogen receptor modulators
US20070111988A1 (en) * 2004-01-22 2007-05-17 Eli Lilly And Company Selective estrogen receptor modulators
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US7262205B2 (en) * 2004-03-11 2007-08-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
RU2547148C2 (ru) * 2005-02-09 2015-04-10 Аркьюл, Инк. Композиции и способы лечения рака
US7655700B2 (en) 2005-08-25 2010-02-02 Michigan State University Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
EP2342189A2 (en) * 2008-09-29 2011-07-13 Eli Lilly And Company Selective estrogen receptor modulator for the treatment of osteoarthritis
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
BR112012032189B1 (pt) 2010-06-16 2020-11-03 Endorecherche, Inc usos de um agonista ou antagonista de lhrh em associação com um modulador de receptor de estrogênio seletivo e com um precursor de esteróide sexual para a preparação de uma medicamento para o tratamento ou prevenção de doenças relacionadas com estrogênio e kits
JP7354123B2 (ja) 2018-02-21 2023-10-02 エイアイ・セラピューティクス・インコーポレーテッド アピリモドとグルタミン酸作動薬を用いた併用療法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3396169A (en) 1966-10-26 1968-08-06 Upjohn Co Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes
FR90418E (fr) * 1962-09-13 1967-12-08 Ici Ltd Nouveaux dérivés alkéniques
US3862232A (en) 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3313853A (en) 1963-10-16 1967-04-11 Upjohn Co 2-(tertiaryaminoalkoxyphenyl)-3, 4-dihydronaphthalenes and 2-(tertiaryaminoalkoxyphenyl) -3, 4- dihydro -1(2h)-naphthalenones
US3293263A (en) 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
US3522319A (en) * 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3320271A (en) 1964-06-01 1967-05-16 Upjohn Co 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
GB1138163A (en) 1965-05-21 1968-12-27 Bristol Myers Co Benzothiophene derivatives having anti-fertility properties
US3394125A (en) 1965-10-23 1968-07-23 Bristol Myers Co 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group
US3483293A (en) 1967-12-15 1969-12-09 Upjohn Co Method for controlling birds and rodents
US3567737A (en) 1968-01-02 1971-03-02 Upjohn Co Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes
IL45454A (en) * 1973-08-31 1977-06-30 Ciba Geigy Ag 3-methyl-4-(p-phenoxy(or benzyl)-phenoxy)-2-butene derivatives their preparation and pest-population contaol compositions containing them
US4230862A (en) 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
GB2097788B (en) * 1981-04-03 1985-04-24 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE3121175A1 (de) * 1981-05-27 1982-12-16 Klinge Pharma GmbH, 8000 München Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8311678D0 (en) 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
FR2599031B1 (fr) * 1986-05-23 1988-07-22 Oreal Nouveaux composes naphtyl aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
US4859695A (en) * 1986-06-10 1989-08-22 Merck & Co., Inc. Antiestrogen agents having anabolic activity in animals
US4851554A (en) * 1987-04-06 1989-07-25 University Of Tennessee Research Corporation Certain 3-substituted 2-alkyl benzofuran derivatives
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5254568A (en) 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
DE4122484A1 (de) 1991-07-06 1993-01-07 Teves Gmbh Alfred Schaltungsanordnung zur erkennung von radsensordefekten
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
JP3157882B2 (ja) 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives

Also Published As

Publication number Publication date
HUT77919A (hu) 1998-10-28
JPH10506392A (ja) 1998-06-23
EP0703228B1 (en) 2002-03-06
CO4410318A1 (es) 1997-01-09
RU2165924C2 (ru) 2001-04-27
ATE214058T1 (de) 2002-03-15
US5484796A (en) 1996-01-16
NZ294177A (en) 1998-10-28
DK0703228T3 (da) 2002-05-21
PE47496A1 (es) 1996-11-12
YU61595A (sh) 1998-09-18
WO1996009039A1 (en) 1996-03-28
CA2200449A1 (en) 1996-03-28
MX9702154A (es) 1997-06-28
MY132075A (en) 2007-09-28
EP0703228A1 (en) 1996-03-27
US5484795A (en) 1996-01-16
DE69525699T2 (de) 2002-11-21
SI0703228T1 (en) 2002-08-31
TW399036B (en) 2000-07-21
AU697114B2 (en) 1998-09-24
PT703228E (pt) 2002-07-31
US5484797A (en) 1996-01-16
KR970705983A (ko) 1997-11-03
NO307929B1 (no) 2000-06-19
PL319454A1 (en) 1997-08-04
TR199501135A2 (tr) 1996-06-21
AU3686395A (en) 1996-04-09
IL115335A0 (en) 1995-12-31
CZ291207B6 (cs) 2003-01-15
DE69525699D1 (de) 2002-04-11
US6437137B1 (en) 2002-08-20
US7501441B1 (en) 2009-03-10
NO971278L (no) 1997-05-14
NO971278D0 (no) 1997-03-19
US6410564B1 (en) 2002-06-25
CZ82297A3 (en) 1997-12-17
ES2173154T3 (es) 2002-10-16
BR9508967A (pt) 1997-12-30
ZA957857B (en) 1997-03-18

Similar Documents

Publication Publication Date Title
IL115335A (en) Naphthyl compounds process for their preparation and pharmaceutical compositions thereof
GEP20084496B (en) Benzothiophene compound, intermediate, composition, and method
NZ315174A (en) Naphthyl and dihydronaphthyl compounds, pharmaceutical compositions and use thereof
CA2228997A1 (en) Benzothiophene compounds
MX9600743A (es) Compuestos de naftilo, intermediarios y composiciones farmaceuticas a partir de los mismos y proceso para su preparacion.
DE69532079D1 (de) Benzofuranverbindungen, präparate und verfahren
DE69707611D1 (de) Dihydronaphthalen- und Naphthalenderivate, Zwischenverbindungen, Zusammensetzungen und deren Herstellungsverfahren
AU3686295A (en) A method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
DE69726513D1 (de) Benzo[B]thiophenverbindungen,Zwischenprodukte,Verfahren,Zusammensetzungen und Methode
PT832881E (pt) Compostos de benzofluoreno intermediarios composicoes e metodos
CA2170479A1 (en) Benzothiophene compounds, intermediates, compositions, and methods
AU2003247589A8 (en) Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them
RS49886B (sr) Benzotiofenska jedinjenja, intermedijari, kompozicije i metode

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed